Case Report on Ulcerative Colitis in 16 year girl

  • MD.Salma Department of Pharmacy Practice, QIS College of Pharmacy,Vengamukkapalem,Ongole,AP,India.
  • Y.Siva Department of Pharmacy Practice, QIS College of Pharmacy,Vengamukkapalem, Ongole, AP,India.
  • J.Bhargava Narendra Department of Pharmacy Practice, QIS College of Pharmacy, Vengamukkapalem, Ongole,AP,India.
    jbn520@gmail.com

Abstract

Ulcerative colitis (UC) is a chronic idiopathic inflammatory disorder that involves any part of the colon starting in the rectum in a continuous fashion presenting typically with symptoms such as bloody diarrhea, abdominal pain, and rectal urgency.The clinical presentation of the disease usually dictates the choice of pharmacologic therapy, where the goal is to first induce remission and then maintain a corticosteroid-free remission. UC is diagnosed based on clinical presentation and endoscopic evidence of inflammation in the colon starting in the rectum and extending proximally in the colon. The choice of treatment depends on severity, localization and the course of the disease. For proctitis, topical therapy with 5-aminosalicylic acid (5-ASA) compounds is used. More extensive or severe disease should be treated with oral and local 5-ASA compounds and corticosteroids to induce remission. Patients who do not respond to this treatment require hospitalization. Intravenous steroids or, when refractory, calcineurin inhibitors (cyclosporine, tacrolimus), tumor necrosis factor-α antibodies (infliximab) or immunomodulators (azathioprine, 6-mercaptopurine) are then called for. Indications for emergency surgery include refractory toxic megacolon, perforation, and continuous severe colorectal bleeding.

Keywords: Inflammatory bowel disease, Colitis, Endoscopy, corticosteroids, immune modulators

Downloads

Download data is not yet available.

References

1. Hoffmann JC, Zeitz M, Bischoff SC, Brambs HJ, Bruch HP, Buhr HJ, Dignass A, Fischer I, Fleig W, Fölsch UR, et al. [Diagnosis and therapy of ulcerative colitis: results of an evidence based consensus conference by the German society of Digestive and Metabolic Diseases and the competence network on inflammatory bowel disease] Z Gastroenterol. 2004;42:979–983.

2. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, et al. European evidence based consensus on the diagnosis and management of Crohn‘s disease: definitions and diagnosis. Gut. 2006;55 Suppl 1:i1–i15.

3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1539087/.

4. Shanahan F. Ulcerative colitis. In: Hawkey CJ, Bosch J, Richter JE, Garcia-Tsao G, Chan FKL, eds. Textbook of Clinical Gastroenterology and Hepatology. 2nd ed. Oxford: Wiley-Blackwell; 2012:355–371.

5. Ko Y, Butcher R, Leong RW. Epidemiological studies of migration and environmental risk factors in the inflammatory bowel diseases. World Journal of Gastroenterology. 2014;20(5):1238–1247.

6. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. American Journal of Gastroenterology. 2011;106(4):563–573.

7. Inflammatory bowel disease (IBD). Centers for Disease Control and Prevention website. www.cdc.gov/ibd External link. Updated January 14, 2014. Accessed July 23, 2014.

8. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology. 2010;105(3):501–523.

9. Walfish AE, Sachar DB. Ulcerative colitis. The Merck Manual website. www.merckmanuals.com External link. Updated December 2012. Accessed July 23, 2014.

10. Gisbert JP, Chaparro M. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. J Crohns Colitis. 2019 Mar 26;13(3):374-384.

11. Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1079-1100.

12. Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. World J. Gastroenterol. 2018 Sep 21;24(35):4014-4020.

13. Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health. 2017 Oct;1(2):147-158.

14. Liu CY, Polk DB. Microbiomes through the Looking Glass: What Do UC? Cell Host Microbe. 2018 Oct 10;24(4):472-474.

15. Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res. 2018 Oct;16(4):522-528.

16. Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. Gastrointest. Endosc. 2018 Dec;88(6):887-898.

17. Terry R, Chintanaboina J, Patel D, Lippert B, Haner M, Price K, Tracy A, Lalos A, Wakeley M, Gutierrez LS. Expression of WIF-1 in inflammatory bowel disease. Histol. Histopathol. 2019 Feb;34(2):149-157.

18. Yamamoto-Furusho JK, Fonseca-Camarillo G, Furuzawa-Carballeda J, Sarmiento-Aguilar A, Barreto-Zuñiga R, Martínez-Benitez B, Lara-Velazquez MA. Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. J Inflamm (Lond). 2018;15:13.

19. Guardiola J, Lobatón T, Cerrillo E, Ferreiro-Iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-Moranta F., en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol. 2018 Oct;41(8):514-529.

20. Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2019 Mar;52(2):129-136.

21. Rodríguez-Lago I, Ferreiro-Iglesias R, Nos P, Gisbert JP., en representación del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. Gastroenterol Hepatol. 2019 Feb;42(2):90-101.

22. Borman ZA, Côté-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Rev Gastroenterol Hepatol. 2018 Nov;12(11):1101-1108.

23. McKenna NP, Bews KA, Behm KT, Mathis KL, Lightner AL, Habermann EB. Do Patients With Inflammatory Bowel Disease Have a Higher Postoperative Risk of Venous Thromboembolism or Do They Undergo More High-risk Operations? Ann. Surg. 2020 Feb;271(2):325-331.

24. Willian MK, D'Haens G, Yarlas A, Joshi AV. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study. J Patient Rep Outcomes. 2018 Dec;2:22.

25. Drews JD, Onwuka EA, Fisher JG, Huntington JT, Dutkiewicz M, Nogalska A, Nwomeh BC. Complications after proctocolectomy and ileal pouch-anal anastomosis in pediatric patients: A systematic review. J. Pediatr. Surg. 2019 Jul;54(7):1331-1339.
Statistics
58 Views | 12 Downloads
Citatons
How to Cite
MD.Salma, M., Y. Y.Siva, and , J. N. , J.Bhargava Narendra. “Case Report on Ulcerative Colitis in 16 Year Girl”. World Journal of Current Medical and Pharmaceutical Research, Sept. 2020, pp. 287-90, doi:10.37022/wjcmpr.vi.154.
Section
Case Reports